ProfileGDS5678 / 1419988_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 78% 77% 76% 79% 77% 79% 77% 77% 76% 76% 78% 75% 77% 78% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.3361978
GSM967853U87-EV human glioblastoma xenograft - Control 25.2319977
GSM967854U87-EV human glioblastoma xenograft - Control 35.1639476
GSM967855U87-EV human glioblastoma xenograft - Control 45.7233379
GSM967856U87-EV human glioblastoma xenograft - Control 55.3011277
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.3724779
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.1799477
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.2843477
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.1608676
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.1684976
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.3341878
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.0668375
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.2626977
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.3493678